Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

Analyst Ratings

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $27.50 (30.95% upside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetActions
4/28/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016JPMorgan Chase & Co.Lower Price TargetOverweight$45.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Barclays PLCBoost Price TargetUnderweight$16.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Robert W. BairdReiterated RatingNeutral$36.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015Leerink SwannLower Price TargetOutperform$42.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015Deutsche Bank AGInitiated CoverageBuy$42.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2014FBR & CoReiterated RatingOutperform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2014Credit Suisse Group AGBoost Price TargetOutperform$43.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q314$1.67$2.61$40.83 million$42.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateHeadline
07/28/16 06:57 AMCan Shares Of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Hit $32? - Investor Newswire
07/26/16 06:41 AMFDA Oks AbbVie' VIEKIRA XR To Treat Genotype 1 Chronic Hepatitis C Virus
07/25/16 09:20 PMEnanta Announces the U.S. Food and Drug …
07/25/16 03:00 AMCHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) - [PR Newswire] - NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the ...
07/23/16 07:55 AMEnanta Pharmaceuticals Inc (NASDAQ:ENTA) Realized Volatility Hits An Elevated Level - CML News
07/23/16 07:55 AMHays Advisory Lowers stake in Enanta Pharmaceuticals Inc (ENTA) - TheFounders Daily
07/22/16 06:31 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 06:31 AMEnanta Pharmaceuticals Inc. (ENTA) Jumps 5.62% on July 21 - Equities.com
07/21/16 04:00 PMStock Soars, Rewards Investors Nicely Today: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Engelwood Daily
07/21/16 12:59 PMETF’s with exposure to Enanta Pharmaceuticals, Inc. : July 21, 2016 -
07/21/16 07:20 AMEnanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for July 19 - Equities.com
07/20/16 05:03 PMIs $32 Price Target Attainable For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)? - Investor Newswire
07/20/16 06:28 AMEquity Roundup: Stock Performance Focus on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph
07/19/16 09:05 PMEnanta Pharmaceuticals to Host Conference Call on August …
07/18/16 08:57 AMShare Performance Summary for: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph
07/18/16 06:30 AMEnanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 P.M. ET to Discuss Financial Results for Its Fiscal Third Quarter Ended June 30, 2016 - [Business Wire] - Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2016 after the U.S.
07/16/16 07:14 AMShares Experiencing a Downtrend: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - TGP
07/14/16 03:29 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 03:29 PMEnanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Short Interest Decreased By 1.75% - Consumer Eagle
07/14/16 07:03 AMShares Losing Ground for the Month; Investor Alert on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Engelwood Daily
07/14/16 07:03 AMAnalyst Target and Average Rating Watch: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph
07/14/16 07:03 AMStrong Sell Calls For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At 1 - Investor Newswire
07/12/16 04:01 PMEnanta Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/12/16 04:00 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/08/16 03:50 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Updated Price Targets - FTSE News
07/07/16 09:01 PMCan Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Improve on the Earnings Front? - Engelwood Daily
07/07/16 06:34 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Expected to Reach Highs Of $32 - Investor Newswire
07/06/16 09:40 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Broker Price Targets For The Coming Week - Fiscal Standard
07/06/16 09:40 PMShare Performance Recap for: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph
07/06/16 09:40 PMCompany Stock Focus for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Which Way Will Shares Head? - Press Telegraph
07/06/16 09:40 PMEnanta Pharmaceuticals Inc. (ENTA) Jumps 5.14% on July 06 - Equities.com
07/01/16 08:54 PMCovering the Bases on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Where is the Stock Going? - Press Telegraph
07/01/16 07:25 AMEnanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Shorted Shares Decreased By 1.75% - Press Telegraph
07/01/16 07:25 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Earnings Glance and Target Price Review - Engelwood Daily
06/30/16 11:01 AMETF’s with exposure to Enanta Pharmaceuticals, Inc. : June 30, 2016 -
06/29/16 03:48 PMStrong Sell Calls Recommendations For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At 1 - Investor Newswire
06/29/16 06:58 AMHow Analysts Feel About Enanta Pharmaceuticals Inc (NASDAQ:ENTA)? - Engelwood Daily
06/23/16 05:48 AMStrong Buy Calls Count For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At 1 - Investor Newswire
06/20/16 03:43 PMEnanta Pharmaceuticals Initiates Proof-of-Concept Study with …
06/20/16 10:02 AMMarket Movers: Alexco Resource Corporation (NYSEMKT:AXU), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), First ... - KC Register
06/20/16 10:02 AMEnanta Pharma (ENTA) Commences EDP-494 Proof-of-Concept Study in Two HCV Genotypes - StreetInsider.com
06/20/16 10:02 AMCan Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Surprise Analysts this Quarter? - Investor Newswire
06/20/16 09:46 AMEnanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus - [Business Wire] - Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated a proof of concept study and has begun dosing with EDP-494, a potent, pan-genotypic cyclophilin inhibitor to treat patients with genotype 1 or genotype 3 chronic hepatitis C virus.
06/16/16 08:12 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Current Analyst Ratings - Fiscal Standard
06/09/16 03:52 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Fundamental Star Rating Report - CML News
06/07/16 03:56 PMENANTA PHARMACEUTICALS INC. (NASDAQ:ENTA) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:12 AMPerformance Review for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - HNN
06/03/16 04:02 PMStock Review and Earnings Check on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - HNN
06/02/16 07:26 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Update & Estimates - Stock Tick Tock - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to post earnings of $-0.11 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 07:26 AMEnanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Shorted Shares Increased 2.06% After Market Selling - HNN - Enanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Shorted Shares Increased 2.06% After Market SellingHNNThe short interest to Enanta Pharmaceuticals Incorporated's float is 20.87%. The stock increased 2.45% or $0.6 during the last trading session, hitting $25.13. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has declined 2.07% since October 26, 2015 and is ...and more »

Social

About Enanta Pharmaceuticals

Enanta Pharmaceuticals logoEnanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program, the Company is developing agonists of the farnesoid X receptor, or FXR, that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC, another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir, ABT-493, EDP-239, ABT-494 and EDP-494.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ENTA
  • CUSIP:
Key Metrics:
  • Previous Close: $21.00
  • 50 Day Moving Average: $22.58
  • 200 Day Moving Average: $26.18
  • P/E Ratio: 12.47
  • P/E Growth: 0.00
  • Market Cap: $402.08M
  • Beta: 0.58
  • Current Year EPS Consensus Estimate: $0.91 EPS
  • Next Year EPS Consensus Estimate: $-1.28 EPS
Additional Links:
Enanta Pharmaceuticals (NASDAQ:ENTA) Chart for Friday, July, 29, 2016